Gongwin Biopharm (共信-KY) presented clinical data for its developmental equine drug, p-TLS, at the 2026 World Equine Veterinary Association (WEVA) Congress. The drug, targeting superficial tumors such as melanomas, squamous cell carcinomas, and sarcomas, demonstrated a 100% tumor ablation rate.

• Technical Edge: Utilizing the company’s "PTS" micro-invasive targeted ablation platform, p-TLS is a small-molecule chemical ablatant injected directly into the tumor. This removes the need for general anesthesia or large-scale surgery—both high-risk and high-cost procedures for horses.
• Market Strategy: GNT believes these results will accelerate expansion into the Middle East and Southeast Asia, while facilitating entry into European and North American markets where equine insurance systems are mature.
• Next Steps: The company plans to initiate field trials in collaboration with the University of Melbourne and the University of Sydney later this year to bolster international validation.

Resource: 共信馬匹新藥 臨床報捷